Natalia Usman

Dr. Natalia Usman

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
APAgnesa V. Panferova
Agnesa V. Panferova
KSKseniya Yu. Sinichenkova
Kseniya Yu. Sinichenkova
MJMeriam Abu Jabal
Meriam Abu Jabal
NUNatalia Usman
Natalia Usman
ASAnastasya S. Sharlai
Anastasya S. Sharlai
ADAlexander E. Druy
Alexander E. Druy
The World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone subdivides rhabdomyosarcomas (RMSs) into alveolar, embryonal, pleomorphic, and spindle cell RMSs. Advances in molecular genetic diagnostics have made it possible to identify new RMS subgroups within traditional morphological entities. One of these subgroups comprises rare tumors characterized by epithelioid and spindle cell morphology, a highly aggressive clinical course with pronounced tendency to intraosseous growth, and the presence of pathognomonic recurring genetic aberrations—chimeric genes/transcripts EWSR1::TFCP2, FUS::TFCP2, or MEIS1::NCOA2. Starting from 2018, only 26 reported cases of RMS have been assigned to this subgroup. The rarity of such tumors hampers their correct diagnostics for both anatomic pathologists and molecular oncologists. Here, we describe a clinical case of intraosseous spindle cell RMSs expressing the EWSR1::TFCP2 fusion gene, encountered for the first time in our practice, in a 16-yr-old female patient presenting with mandibular lesion. The diagnostic process took considerable time and involved RNA sequencing—a high-throughput method of molecular genetic research. The tumor was extremely aggressive, showing resistance to polychemotherapy, radiation therapy, and crizotinib-targeted therapy, with the fatal outcome.

15 December 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NANatalia Andreeva
Natalia Andreeva
NUNatalia Usman
Natalia Usman
ADAlexander Druy
Alexander Druy

Verified
Journal Article
Open access
PDF file
TBTatiana Budagova
Tatiana Budagova
AEAnna Efremova
Anna Efremova
NUNatalia Usman
Natalia Usman
DMDiana Mokrousova
Diana Mokrousova
DGDmitry Goldshtein
Dmitry Goldshtein
Cancers constitute a leading cause of mortality. Chimeric antigen receptor (CAR) cell therapies provide breakthrough solutions for various cancers while posing considerable risks of immunological side reactions. Of various cytotoxic lymphocyte subsets, natural killer (NK) cells are considered the least immunogenic. Obtaining viable NK cells with stable phenotypes in quantities sufficient for modification is technologically challenging. The candidate sources include primary mononuclear cell cultures and immortalized NK cell lines; alternatively, the clinical-grade NK cells can be differentiated from induced pluripotent stem cells (iPSCs) by a good manufacturing practice (GMP)-compatible xeno-free protocol. In this review, we analyze existing protocols for targeted differentiation of human iPSCs into NK cells with a focus on xeno-free requirements.

Verified
Journal Article
Open access
PDF file
NANataliya A. Andreeva
Nataliya A. Andreeva
TSTatyana V. Shamanskaya
Tatyana V. Shamanskaya
DKDenis Kachanov
Denis Kachanov
NZNikolay V. Zhukov
Nikolay V. Zhukov
NGNina V. Gegeliya
Nina V. Gegeliya
ADAlexander E. Druy
Alexander E. Druy
Next-generation sequencing (NGS) is instrumental for clinical decisions on molecularly targeted therapy (TT). In pediatric oncology, TT is a relatively rare choice administered chiefly on a tumor-agnostic basis. The investigation enrolled 304 pediatric patients with extracranial solid tumors that were diagnosed and treated in 2018–2023. Tumor DNA was sequenced using a customized QiaSeq panel (Qiagen, Hilden, Germany) of genes known to be relevant for pediatric solid tumors, including ALK, BRAF, BRCA1/2, EGFR, FGFR1, KIT, MAP2K1/2, NF1, PDGFRA/B, PIK3CA, PTEN, PTPN11, RAS family genes, etc. The assay allowed detection of nucleotide substitutions and small insertions/deletions, as well as gene copy number alterations. TT sensitivity predictors were identified in 120/304 cases (39.5%): Tier II in 83 patients, Tier IB in 32 patients (almost always ALK in neuroblastoma, n = 31) and Tier IA in 5 patients: BRAF p.V600E (n = 3) and NF1 aberrations (n = 2). TT commenced in 21/304 cases (6.9%), often first-line or as a first relapse therapy (14/21 cases), combined with chemotherapy (TT-CT) in 13 cases. The median of TT duration was 10.9 (range 0.8–43.5) months for single-mode and 12.3 (0.3–61.5) months for TT-CT. Clinical benefit rate was achieved in 14/21 patients (66.7%). At the time of writing, nine patients (42.8%) have no progression and are still on treatment for 30.4 months (range 10.3–40.5) after the start of TT. The median time to the best response to TT was 6 (range 0.8–12.3) months. The tolerance was generally good: the therapy was discontinued for toxicity in only one case. The study provides a TT-focused prospective analysis still rare in pediatric oncology. The outcomes indicate satisfactory tolerance and promising efficacy of TT, prompting an update of current treatment standards for several pediatric cancers.

17 June 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
LPLudmila Papusha
Ludmila Papusha
MZMargarita Zaytseva
Margarita Zaytseva
MSMaria Senchenko
Maria Senchenko
ASAgunda Sanakoeva
Agunda Sanakoeva
APAgnesa Panferova
Agnesa Panferova
ADAlexander E. Druy
Alexander E. Druy

28 October 2024 in Bulletin of Russian State Medical University
Verified
Journal Article
Closed access
DSDA Sukhov
DA Sukhov
IKIv Kholoshenko
Iv Kholoshenko
TPTv Petrova
Tv Petrova
GRGa Romanenko
Ga Romanenko
MMMyu Myshkin
Myu Myshkin
EBEv Barsova
Ev Barsova
The novel ribonuclease inhibitor LoRI is a 63 kDa recombinant protein optimized for high-throughput expression in E. coli and purification by metal chelate affinity chromatography (IMAC). The product was obtained by N-terminal fusion of mouse placental RNase inhibitor polypeptide to a thioredoxin module. Advantage of the engineering strategy in terms of protein structure and function was predicted in silico. Under laboratory settings, the yield of purified soluble recombinant product was about 12 mg per 1 L of expression bacterial culture. By RNase inhibition capacity in vitro, the product is comparable or superior to a commercial reference. The kinetic data comply with Lineweaver-Burk model.